Dose-escalation cohorts (3+3 design): modified dosing schema. Four dosing cohorts received venetoclax ranging from 200 to 800 mg every day plus R-CHOP or G-CHOP. Standard CHOP chemotherapy was administered consisting of IV cyclophosphamide 750 mg/m², IV doxorubicin 50 mg/m², and IV vincristine 1.4 mg/m² (with a 2.0-mg cap) on day 1, and prednisone 100 mg/day orally on days 1 to 5. A 6-week (ie, 2-cycle) observation period was allowed for evaluation of DLTs. Patients who experienced responses without excessive toxicity were allowed up to 8 cycles of CHOP at the investigator’s discretion after discussion with the Medical Monitor. D, day; W, week.